Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17

Justin C Yang*, Andres Roman-Urrestarazu, Carol Brayne

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)

Abstract

BACKGROUND: Access to adequate treatment for opioid use disorder (OUD) has been a high priority among American policymakers. Elucidation of the sociodemographic and institutional differences associated with the use, or lack thereof, of opioid agonist therapy (OAT) provides greater clarity on who receives OAT. Timely access to care is a further consideration and bears scrutiny as well.

METHODS: We draw upon data from the Treatment Episode Data Set-Admissions (TEDS-A) to analyse the relationship between sociodemographic and institutional characteristics and the receipt of opioid agonist treatments and time waiting to enter treatment.

RESULTS: Estimates from logistic regression models highlight certain groups which show lower odds of receipt of OAT, including those in precarious housing arrangements, those unemployed or not otherwise in the labor force, and those referred by drug abuse care providers, educational institutions, employers, and the criminal justice system. Groups which showed higher odds of waiting over a week to enter treatment included those who were separated, divorced, or widowed, those working part-time, and those referred by drug abuse care providers, employers, and the criminal justice system.

CONCLUSION: Given the efficacy of OAT and the adverse outcomes associated with long waiting times, coordinated effort is needed to understand why these differences persist and how they may be addressed through appropriate policy responses.

Original languageEnglish
Article numbere0226349
Pages (from-to)e0226349
Number of pages16
JournalPLOS ONE
Volume14
Issue number12
DOIs
Publication statusPublished - 12 Dec 2019

Keywords

  • MEDICATION-ASSISTED TREATMENT
  • SUBSTANCE-ABUSE TREATMENT
  • METHADONE-MAINTENANCE
  • OLDER-ADULTS
  • BUPRENORPHINE
  • DETERMINANTS
  • PHYSICIANS
  • MORTALITY
  • BARRIERS
  • THERAPY

Cite this